Searchable abstracts of presentations at key conferences in endocrinology

ea0067gp23 | Poster Presentations | EYES2019

A rare case of adrenal incidentaloma- pheochromocytoma presenting with anemia, thrombocytosis, and proteinuria. A case report and review of the literature

Mavroeidi Ioanna , Boutati Eleni , Anagnosti Vasiliki , Economopoulos Nikolaos , Peppa Melpomeni

Introduction: Pheochromocytoma (PHEO) is a rare neuroendocrine tumor, which presents with various clinical phenotypes, depending on the size of the tumor, the secreting activity, and the secreting product. Large PHEOS exhibit symptoms related to mass effects and malignant PHEOS symptoms related to metastases. Some PHEOS present as adrenal incidentalomas (AI) or with an unusual clinical phenotype.Case report: A 54-year-old Russian female presented with se...

ea0063p20 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

A case series of metastatic pheochromocytomas and paragangliomas: patients characteristics, therapeutic approach and follow-up

Angelousi Anna , Kassi Eva , Peppa Melpomeni , Chrysoulidou Alexandra , Zografos George , Aggeli Chrysanthi , Kaltsas Grigorios

Background: Metastatic pheochromocytomas (PCs) and paragangliomas (PGLs) are rare neuroendocrine neoplasms with a <1:106 incidence, defined by the presence of metastatic disease besides recurrent or locally invasive disease.Aim: Retrospective analysis of clinical, biochemical/hormonal, imaging, genetic and histopathological features of patients with malignant PCs/PGLs diagnosed over 15 years.Results: Thirteen patient...

ea0016p331 | Endocrine tumours | ECE2008

Novel MEN1 germline mutations and clinical features in Greek patients with multiple endocrine neoplasia type 1

Peppa Melpomeni , Pikounis Vasilios , Kamakari Smaragda , Peros George , Economopoulos Theofanis , Raptis Sotirios A , Hadjidakis Dimitrios

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant hereditary disorder, associated with mutations of the MEN1 gene, characterised by the combined occurrence of tumours of the parathyroid glands, the pancreatic islet cells and the anterior pituitary.Aim: To identify MEN1 gene mutations and characterize clinical manifestations in Greek patients with MEN1.Patients and methods: We studied 4 ...

ea0041ep906 | Pituitary - Clinical | ECE2016

Quality of life in patients with acromegaly and the effect of somatostatin analogues

Kaldrymidis Dimitrios , Papadakis Georgios , Tsakonas Georgios , Kostoglou-Athanassiou Ifigenia , Kaldrymidis Philippos , Peppa Melpomeni , Roussou Paraskevi , Diamanti-Kandarakis Evanthia

Objective: Quality of life is currently considered a major factor in the assessment of disease outcome. The aim was to assess quality of life in acromegaly and the effect of somatostatin analogues on it.Design: This study included 101 patients with acromegaly, mean age 59.51±1.35 years (mean ± S.E.M.), with a disease duration of 12.88±0.96 years. All subjects completed the Acromegaly Quality of Life Questionnaire (AcroQoL) w...

ea0016p800 | Thyroid | ECE2008

Insulin resistance and oxidative stress induce advanced glycation end products formation in patients with clinical and subclinical hypothyroidism

Peppa Melpomeni , Hadjidakis Dimitrios , Alevizaki Maria , Dimitriadis George , Isari Georgia , Economopoulos Theofanis , Uribarri Jaime , Vlassara Helen , Raptis Sotirios A

Introduction: Advanced glycation end products (AGEs) formation is accelerated in various pathological conditions characterized by insulin resistance (IR) and/or increased oxidative stress (OS). Hypothyroidism – overt (OH) or subclinical (SUH) – is associated with a variety of metabolic disorders leading to IR and increased OS.Aim: To estimate the εN-carboxymethyl-lysine (CML) levels, in subjects with OH and SUH and seek f...

ea0099p199 | Late-Breaking | ECE2024

Endocrine toxicity is an independent predictor of survival in lung cancer patients treated with immune checkpoint inhibitors

Ntouraki Sofia , Panagiotou Emmanouil , A. Vathiotis Ioannis , Effrosyni Livanou Maria , Trimis Athanasios , Charpidou Andriani , Syrigos Konstantinos , Peppa Melpomeni

Lung cancer (LC) is a serious health problem worldwide. Survival outcomes have improved over time, due to the widespread adoption of therapeutic agents, including immune checkpoint inhibitors (ICIs). Endocrine immune-related adverse events (irAEs) are common in LC patients treated with ICIs. A retrospective study of LC patients was performed in a tertiary center for cases seen between January 2014 and October 2023. In total, 983 LC patients were included in the study, with a m...

ea0041ep890 | Pituitary - Clinical | ECE2016

High incidence of thyroid cancer among patients with acromegaly

Kaldrymidis Dimitrios , Papadakis Georgios , Tsakonas Georgios , Kaldrymidis Philippos , Flaskas Theofanis , Seretis Andreas , Pantazi Eleni , Kostoglou-Athanassiou Ifigenia , Peppa Melpomeni , Roussou Paraskevi , Diamanti-Kandarakis Evanthia

Introduction: Several studies have suggested that patients with acromegaly have an increased risk of thyroid, colorectal, breast and prostate tumors. We determined the prevalence of malignant neoplasms in patients with acromegaly in a single Greek Centre during the years 1995–2015.Methods: We evaluated cancer risk in a cohort of 110 patients (M/F 48/62, age 58.63±13.8 years, range 30–86) with acromegaly. Mean age at diagnosis of acromegaly...

ea0099ep281 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Fluasterone buccal tablets: a promising therapy for the metabolic effects of hypercortisolemia and cushing syndrome

Vrachnis Dionysios , Efstathiadou Zoi , Goulis Dimitrios , Kassi Eva , Lymniati Christina , Ntali Georgia , Peppa Melpomeni , Stavrinos Konstantinos , Vryonidou Andromahi , Xekouki Paraskevi , Stratakis Constantine

Fluasterone (16-α-fluoro-5-androsten-17-one) is a structural analogue of dehydroepiandrosterone (DHEA) that retains DHEA clinical properties without its androgenic effects. In animal models, fluasterone exhibits DHEA-like effects, including anti-inflammatory, anti-proliferative, and anti-diabetic properties but is consistently more potent than DHEA. An orphan-drug designation for fluasterone has been granted by the FDA for treatment of Cushing’s syndrome (CS), includ...